USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: XERIS PHARMACEUTICALS, INC.
Address: 3208 Red River Street
Suite 300
Austin, TX 78705-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,179,571.00 3
SBIR Phase II $1,707,856.00 2

Award List:

IMPROVED HYPOGLYCEMIA RESCUE DEVICE

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: John Kinzell
Award Amount: $157,478.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this program is to develop of a clinical prototype, semi-solid drug formulation and auto-injector pen that deliver microliter volumes of a glucagon dose without reconstitution for hypoglycemic emergenci es. To assess the feasibility of this… More

Improved Hypoglycemia Rescue Device

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: John Kinzell – 415-472-4623
Award Amount: $994,123.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this project is to demonstrate the safety, pharmacokinetics and initial efficacy of a ready-to-use Glucagon Rescue Pen that will deliver a very low volume dose of a glucagon without reconstitution for hypoglycemic emergencies. To execute on this… More

Clinical Development of a Stable Glucagon Formulation for Bi-hormonal Pump

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Steven Prestrelski – 510-742-9700
Award Amount: $343,124.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this program is to further the development of a novel, stable, non-aqueous glucagon formulation as an integral component of a bi-hormonal (insulin-glucagon) pump system for treatment of persons with diabetes. The addition of glucagon to the… More

Development of an Electromyographically Controlled Electrolarynx Voice Prosthesis

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: John Kinzell – 888-570-4781
Award Amount: $678,969.00
Abstract:
DESCRIPTION (provided by applicant): The program outlined in this application has been designed to accelerate the development and commercialization of a Glucagon Mini-Dose Pen to change the paradigm for treatment of moderate hypoglycemia in insulin-using diabetics. This research is directly relevant… More

Clinical Development of a Stable Glucagon Formulation for Bi-hormonal Pump

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Steven Prestrelski – 858-414-1014
Award Amount: $713,733.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this program is to further the development of a novel, stable, non-aqueous glucagon formulation as an integral component of a bi-hormonal (insulin-glucagon) pump system for treatment of persons with diabetes. The addition of glucagon to the… More